Insights
About
About

Startup News: SandboxAQ acquires Good Chemistry

In recent days, several privately held biotech companies have either been part of a merger deal or filed papers to go public.

Last week, Good Chemistry, which uses AI and other advanced technologies to accelerate drug discovery, announced that it was being acquired by SandboxAQ, an AI and quantum software company with a last known valuation of $3.85 billion as of March 2022. Though the press release announcing the deal didn’t disclose the sales price, The Wall Street Journal reported that the acquisition was worth about $75 million through a combination of cash and stock, according to sources with knowledge of the acquisition.

SandboxAQ’s takeover of Good Chemistry is emblematic of efforts to use new technologies like AI to speed up the pace and affordability of drug development. According to the release announcing the deal, the acquisition is set to improve SandboxAQ's existing computational chemistry and simulation capabilities, “adding additional talent, proven technologies, and deep industry insights gleaned from working with leaders in the life sciences and advanced materials fields.”

Good Chemistry founder and CEO Arman Zaribafiyan will join SandboxAQ with the title of Head of Product for AI Simulation Platforms, according to the announcement.

ArriVent and Fractyl Plan to go public

Meanwhile, two other companies, ArriVent Biopharma and Fractyl Health, announced plans to launch IPOs.

ArriVent Biopharma, which is developing a novel inhibitor for lung cancer, filed earlier this month with the SEC to raise up to $100 million in an IPO, according to Renaissance Capital, an IPO research and investment management firm. ArriVent, which was founded in 2021, plans to list on the Nasdaq under the symbol AVBP.

The company’s lead drug candidate, furmonertinib, is a growth factor receptor mutant-selective tyrosine kinase inhibitor that the company is developing for non-small cell lung cancer. Furmonertinib is currently being evaluated in multiple trials, including a Phase 3 trial.

Fractyl, a biotech that is developing gene therapies for type 2 diabetes and obesity, filed with the SEC to raise up to $100 million in an IPO according to another article in Renaissance Capital. Fractyl’s lead drug candidate, the Revita DMR System, has already been approved for patients in Europe with inadequately controlled type 2 diabetes.

Founded in 2010, the company plans to list on the Nasdaq under the symbol GUTS.

Please Read These Important Legal Notices & Disclosures

The information and material presented in this article is provided for your informational purposes only and does not constitute an offer by Forge Europe GmbH or Forge Europe UK Limited or any of its affiliates to sell, or a solicitation of an offer to buy any securities and may not be used or relied upon in connection with any offer or sale of securities.

If you are a resident or a company registered within Germany this content is for marketing purposes only and on behalf of Forge Europe GmbH of Unter den Linden 38, 10117 Berlin, Germany (registered in the District Court Berlin (Charlottenburg) HRB 240763). Forge Europe GmbH is a tied agent in accordance with §3 (2) WpIG and provides investment brokerage, pursuant to §2 (2) Nr. 3 WpIG, exclusively in the name, on the account and under the liability of Effecta GmbH, Florstadt. If you are resident or a company registered within the United Kingdom or Gibraltar this content is for general marketing purposes only and not a financial promotion on behalf of Forge Europe UK Limited of 10 York Road, London, SE1 7ND, England (registered in England and Wales with company number 14877431). Forge Europe UK Ltd is an Appointed Representative of Sapeno Partners LLP which is authorised and regulated by the Financial Conduct Authority.

Forge Europe GmbH and, its wholly owned subsidiary, Forge Europe UK Limited (together “Forge Europe”) accept liability to a client as set out in the individual agreement entered into with the client. All other liability to any client is expressly excluded to the fullest extent permitted by applicable laws and regulations. Each Forge Europe company expressly excludes all liability to the fullest extent permitted by applicable laws and regulations to any person who is not a client. You will only be a client if you have entered into a written client agreement with the relevant Forge Europe company. To the extent information about or defining specific terms is provided herein, Forge Europe makes no representations as to its accuracy and has no duty to update such information. Such information is based on experience Forge Europe and its affiliates and the meanings and connotations of terms as Forge Europe typically uses and interprets them. Others may construe such terms differently, and you should do your own research and consult with financial, legal and tax professionals regarding any such concepts included herein.

This article does not constitute an offer to provide investment advice or service. Forge Europe does not (1) advise any member on the merits or prudence of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative, involving a high degree of risk, and investors should be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks and investors should conduct their own, independent due diligence regarding the investment, including obtaining additional information about the company, opinions, financial projections and legal or investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. Past performance Is not indicative of future results.

This material may be distributed to, or directed at, only the following persons: (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “FP Order”), (ii) high-net-worth entities falling within Article 49(2) of the FP Order, and (iii) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “FPO Relevant Persons”). Persons who are not FPO Relevant Persons must not act on or rely on this material or any of its contents. Any investment or investment activity to which this material relates is available only to FPO Relevant Persons and will be engaged in only with FPO Relevant Persons. Recipients must not distribute, publish, reproduce, or disclose this material, in whole or in part, to any other person. This content is for the sole use of the intended recipient(s). Any unauthorized review, use, disclosure or distribution is prohibited.